Company intelligence / Profile preview
AiViva BioPharma
Costa Mesa, California, United Statesaiviva.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Completed Phase 1/2 clinical trial of AIV001 for nonmelanoma skin cancer (December 2023). Initiated Phase 1 clinical trial of AIV007 for Age-Related Macular Degeneration and Diabetic Macular Edema (May 2023). Received FDA clearance to administer AIV001 in facial skin by intradermal injection for nonmelanoma skin cancer (December 2024).
- Therapeutic areas
- OphthalmologyOncologyDermatology
- Modalities
- Small molecules (including axitinib/AIV001)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on AiViva BioPharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AiViva BioPharma.